Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564211 | 1.00 | OR51E2 (0.59) | OR51E2LMNAALDH1A1TDP1AKR1B1 | |
| SCHEMBL9333820 | 1.00 | OR51E2 (0.59) | OR51E2LMNAALDH1A1TDP1AKR1B1 | |
| SCHEMBL11341926 | 0.81 | — | — | |
| SCHEMBL12779130 | 0.81 | — | — | |
| SCHEMBL12779119 | 0.81 | — | — | |
| SCHEMBL30544884 | 0.81 | — | — | |
| SCHEMBL13895429 | 0.81 | — | — | |
| SCHEMBL23728418 | 0.78 | OR51E2 (0.46) | OR51E2LMNATDP1PDE4AL3MBTL1 | |
| SCHEMBL7782071 | 0.78 | OR51E2 (0.46) | OR51E2LMNATDP1PDE4AL3MBTL1 | |
| SCHEMBL11649679 | 0.78 | OR51E2 (0.46) | OR51E2LMNATDP1PDE4AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | claimed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC | 2021-11-25 | — | — | US | claimed |
| WO-2021158574-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-106714856-B | Composition containing glycosaminoglycan and protein | 尚卓耐斯特公司 | 2020-03-03 | — | — | CN | claimed |
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | disclosed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158574-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| CN-103131123-B | Polyacetal resin composite | 宝理塑料株式会社 | 2017-08-25 | — | — | CN | disclosed |
| US-5318989-A | Antitumor and -carcinogenic agents; antibiotics; aglycones of esperamycins and calichemicins and having the same mechanism of bioactivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0538898-A2 | Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof | Bristol-Myers Squibb Company (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5198560-A | Antitumor agents based on esperamicin antibiotics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| EP-0454146-A1 | Cytotoxic bicyclo[7.3.1] tridec-4-ene-2,6-diyne compounds and process for the preparation thereof | Bristol-Myers Squibb Company (US) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131040-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR1, CNR2, OPRD1 | OR51E2 1657/4885LMNA 1677/4885ALDH1A1 4149/4885 |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | CNR2, CNR1, FAAH | OR51E2 3823/4885LMNA 1759/4885ALDH1A1 1901/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | OR51E2 2530/4885LMNA 1799/4885ALDH1A1 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.